Effect of tiotropium on heart rate variability in stable chronic obstructive pulmonary disease patients

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 28, Issue 2, 2015, Pages 100-105

  Wu, Yao Kuang ^a,b   Huang, Chun Yao ^a   Yang, Mei Chen ^a,b   Huang, Guo Liang ^a   Chen, Sin Yi ^a   Lan, Chou Chin ^a,b  

^a TAIPEI TZU CHI HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

adverse event; anticholinergic agent; autonomic function; chronic obstructive pulmonary disease; heart rate variability; sympathetic system; tiotropium

Indexed keywords

TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART RATE VARIABILITY; HUMAN; LONG TERM CARE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PULSE OXIMETRY; QUALITY OF LIFE; AGED; CONVALESCENCE; DRUG ADMINISTRATION; DRUG EFFECTS; HEART RATE; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RECOVERY OF FUNCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84926374578     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2014.1125     Document Type: Article

References (36)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Vancouver, WA: Global Initiative for Chronic Obstructive Lung Disease; 2011 [updated Dec 2011]. Available at: www.goldcopd.org/uploads/users/files/GOLD-Report-2013 .pdf. Accessed February 12, 2013.
2. Cazzola M, Page C, and Matera MG: Long-Acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26:307-337.
3. Gross NJ: Ipratropium bromide. N Engl J Med. 1988;319: 486-494.
4. Ferguson GT, and Cherniack RM: Management of chronic obstructive pulmonary disease. N Engl J Med. 1993;328: 1017-1022.
5. Keating GM: Titropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012;72:273-300.
6. Haddad EB, Mak JC, and Barnes J: Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol. 1994;45:899-907.
7. Singh S, Loke YK, and Furberg CD: Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-Analysis. JAMA. 2008;300: 1439-1450.
8. Jenkins CR, and Beasley R: Tiotropium increases the risk of mortality. Thorax. 2013;68:5-7.
9. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, and Lai MS: Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison metaanalysis of randomised controlled trials. Thorax. 2013;68: 48-56.
10. Kesten S, Leimer I, and Jara M: Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease. (Letter) JAMA. 2009;301:1224; author reply 1225-1226.
11. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
12. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, and Tashkin DP: Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137:20-30.
13. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators: Titropium Respimat inhaler and the risk of death in COPD. N Eng J Med. 2013;369:1491-1501.
14. Bartels MN, Jelic S, Ngai P, Basner RC, and De Meersman RC: High-frequency modulation of heart rate variability during exercise in patients with COPD. Chest. 2003;124: 863-869.
15. Chhabra SK, and De S: Cardiovascular autonomic neuropathy in chronic obstructive pulmonary disease. Respir Med. 2005;99:126-133.
16. Scalvini S, Porta R, Zanelli E, Volterrani M, Vitacca M, Pagani M, Giordano A, and Ambrosino N: Effects of oxygen on autonomic nervous system dysfunction in patients with chronic obstructive pulmonary disease. Eur Respir J. 1999;13:119-124.
17. Bedard M-E, Marquis K, Poirier P, and Provencher S: Reduced heart rate variability in patients with chronic obstructive pulmonary disease independent of anticholinergic or b-Agonist medications. COPD. 2010;7:391-397.
18. Kleiger RE, Stein PK, and Bigger JT Jr.: Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol. 2005;10:88-101.
19. Yoshimura K, Maskura R, Hiraga T, Kitada S, Miki K, Miki M, and Tateishi Y: Effects of titropium on sympathetic activation during exercise in stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2012;7:109-118.
20. Nojiri T, Yamamoto K, Maeda H, Takeuchi Y, Funakoshi Y, Maekura R, and Okumura M: Effects of inhaled tiotropium on left ventricular diastolic function in chronic obstructive pulmonary disease patients after pulmonary resection. Ann Thorac Cardiovasc Surg. 2012;18:206-211.
21. Burge S, and Wedzicha JA: COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41: 46-53.
22. Chen JY, Lee YL, Tsai WC, Lee CH, Chen PS, Li YH, Tsai LM, Chen JH, and Lin LJ: Cardiac autonomic functions derived from short-term heart rate variability recordings associated with heart rate recovery after treadmill exercise test in young individuals. Heart Vessels. 2011;26:282-288.
23. Bartels MN, Jelic S, Gonzalez JM, Kim W, and De Meersman RE: Reproducibility of heart rate and blood pressure variability in patients with chronic obstructive pulmonary disease. Clin Auton Res. 2004;14:194-196.
24. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152: 1107-1136.
25. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J. 2005;26:319-338.
26. Wang KY, Chiang CH, Maa SH, Shau WY, and Tarn YH: Psychometric assessment of the Chinese language version of the St. George's Respiratory Questionnaire in Taiwanese patients with bronchial asthma. J Formos Med Assoc. 2001; 100:455-460.
27. Cavaillés A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, Meurice JC, Morel H, Person-Tacnet C, Leroyer C, and Diot P: Comorbidities of COPD. Eur Respir Rev. 2013;22:454-475.
28. Asakura Y, Nishimura N, Maezawa K, Terajima T, Kizu J, and Chohnabayashi N: Effect of switching tiopropium HandiHaler-to Respimat-Soft MistTM Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv. 2013;26:41-45.
29. Ram FS, Carvallho CR, and White J: Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J Chron Obstruct Pulmon Dis. 2011;6:129-139.
30. Singh S, Loke YK, Enright P, and Furberg CD: Proarrhythmic and pro-ischemic effects of inhaled anticholinergic medications. Thorax. 2013;68:114-116.
31. Ichinose M, Fujimoto T, and Fukuchi Y: Tiotropium 5 lg via Respimat and 18 lg via HandiHaler: efficacy and safety in Japanese COPD patients. Respir Med. 2010;104:228-236.
32. Hohlfeld JM, Sharma A, van Noord JA, Cornelissen PJ, Derom E, Towse L, Peterkin V, and Disse B: Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54:405-414.
33. Stewart AG, Waterhouse JC, and Howard P: Cardiovascular autonomic nerve function in patients with hypoxaemic chronic obstructive pulmonary disease. Eur Resp J. 1991;4:1207-1214.
34. Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, and Stukel TA: Cardiovascular safety of inhaled long-Acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013; 173:1175-1185.
35. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ: A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax. 2000;55:289-294.
36. Cheyne L, Irvin-Sellers MJ, and White J: Tiotropium versus ipratropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;9:CD009552.